Dupixent MDL status conferences: what the new schedule means for CTCL families

✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney

Last reviewed: October 8, 2026.

A court calendar is not exciting news. In the Dupixent CTCL MDL, though,
it is still worth noting.

Public docket reporting reviewed this week says the court entered
Procedure Order No. 2 on October 7, after the first case-management
conference. The order reportedly puts several status conferences on the
calendar: December 17, 2026; February 22, 2027; May 17, 2027; September
2, 2027; and December 9, 2027. The parties are expected to file joint
status letters before those conferences.

That is the update. It is useful, but it is easy to misread.

A status date is not a settlement date. It is not a trial date. It is
not a ruling that Dupixent caused anyone's cutaneous T-cell lymphoma. It
is the court asking the lawyers to come back at regular intervals and
explain where the MDL stands.

Our main Dupixent lawsuit
hub covers the
broader allegations against Sanofi and Regeneron. This article is
narrower: what the new status schedule means for people trying to keep
their CTCL records in order.

What the court calendar actually tells us

The Judicial Panel on Multidistrict Litigation created MDL No. 3180 on
June 4, 2026. The cases were sent to the District of New Jersey before
Judge Zahid N. Quraishi. The JPML said the lawsuits share common
questions about the science, what the companies allegedly knew, and
whether the warnings were adequate.

Those questions have not been answered.

The court's first procedure order set the October 1 management
conference and paused formal discovery and answer deadlines until
further order. That early pause is normal in a new products MDL. The
court has to decide how the case will be organized before everyone
starts fighting over documents and depositions.

The newly reported status dates are part of that housekeeping. They give
the court a way to check whether leadership issues, discovery plans,
direct filing, fact sheets, or proposed orders are ready. The schedule
also gives families something more reliable than rumor: actual future
court dates.

But a date on the calendar does not tell you who qualifies, what any
claim is worth, or when a first trial might happen.

December is not a reason to wait

The first listed status conference is December 17, 2026. Families do not
need to sit still until then.

A Dupixent CTCL review usually turns on records, not headlines. The
important papers may be split across a dermatologist, an oncologist, a
pathology lab, a specialty pharmacy, an insurer, and an old patient
portal. Sometimes the visit note is easy to download, while the biopsy
report takes a signed request and two follow-up calls.

Start with the documents that lock down dates:

the Dupixent start date, dose, prescriber, pharmacy, and stop date;
dermatology notes before and during treatment;
biopsy, pathology, and immunohistochemistry reports;
oncology records showing CTCL, mycosis fungoides, Sézary syndrome, or another T-cell lymphoma diagnosis;
earlier biopsies or notes that called the condition eczema, dermatitis, rash, plaques, or something inconclusive.

The earlier records matter because CTCL can look like eczema at first. A
patient may remember years of a stubborn rash. The chart may show a more
useful sequence: treatment changes, repeat biopsies, pathology language,
and the date a doctor finally used the lymphoma diagnosis.

We covered the records issue in more detail here: Dupixent MDL
discovery stay: why CTCL records still
matter.

Keep the safety-signal issue in its lane

The FDA safety-signal language is part of the story, but it should not
be stretched.

A signal means FDA identified a possible issue for evaluation. It is not
a recall. It is not a public finding that Dupixent caused CTCL in a
specific patient. The current DailyMed prescribing information is also a
source to read carefully, because the lawsuits focus in part on what the
official warnings did and did not say.

For a closer look at that point, see our Dupixent CTCL FDA safety
signal
explainer.

The wording of the diagnosis still matters

The JPML order focused on CTCL and CTCL subtypes. It also discussed
arguments about other T-cell lymphomas but did not finally decide
whether non-cutaneous T-cell lymphoma cases belong in the MDL.

That is why the actual pathology wording matters. CTCL, mycosis
fungoides, Sézary syndrome, peripheral T-cell lymphoma, and anaplastic
large cell lymphoma are not interchangeable labels. If the portal
summary is vague, ask for the full biopsy and oncology reports.

Do not round the diagnosis up or down. The document is better than the
memory.

FAQ

Does the new schedule mean there is a Dupixent settlement?

No. The sources reviewed for this article do not show a settlement fund
or a settlement date.

Did the court decide causation?

No. The JPML transfer order lists common questions for coordinated
pretrial work. It does not decide whether Dupixent caused or accelerated
CTCL in any person.

Should patients wait for the December conference before collecting records?

No. Records can take time to gather, and the next court date does not
pause a person's medical history or legal deadline.

Is this MDL a class action?

No. MDL No. 3180 coordinates related federal cases for pretrial work.
Each person's claim still depends on that person's facts, records,
diagnosis, and deadlines.

Attorney advertising and informational disclaimer

This article is general information and may be attorney advertising. It
is not medical advice and does not create an attorney-client
relationship. Speak with a doctor about medical questions and with a
lawyer about deadlines or claim-specific legal advice.

Sources

Robert B. Baker, Board-Certified Civil Trial Attorney

Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →